MARKET

NERV

NERV

Minerva Neurosci
NASDAQ
4.800
+0.580
+13.74%
After Hours: 4.750 -0.05 -1.04% 19:41 02/06 EST
OPEN
4.290
PREV CLOSE
4.220
HIGH
4.920
LOW
4.130
VOLUME
78.07K
TURNOVER
--
52 WEEK HIGH
12.46
52 WEEK LOW
1.150
MARKET CAP
207.72M
P/E (TTM)
-2.5901
1D
5D
1M
3M
1Y
5Y
1D
Analysts Have Conflicting Sentiments on These Healthcare Companies: Minerva Neurosciences (NERV), Gossamer Bio (GOSS) and Merck & Company (MRK)
TipRanks · 3d ago
Analysts Have Conflicting Sentiments on These Healthcare Companies: Minerva Neurosciences (NERV) and Verastem (VSTM)
TipRanks · 3d ago
Minerva Neurosciences veröffentlicht Präsentation zu neuem Therapieansatz für Negativsymptome bei Schizophrenie
Reuters · 4d ago
Minerva Neurosciences Unveils Roluperidone Phase 3 Trial Plans for Negative Symptoms of Schizophrenia
Reuters · 4d ago
Minerva Outlines Confirmatory Phase 3 Plan for Roluperidone
TipRanks · 4d ago
Minerva Neurosciences to Host Virtual Key Opinion Leader Event
Reuters · 4d ago
Minerva Neurosciences kündigt virtuelle Expertenveranstaltung zu Phase-3-Studie mit Roluperidon an
Reuters · 4d ago
Weekly Report: what happened at NERV last week (0126-0130)?
Weekly Report · 5d ago
More
About NERV
Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company, which is focused on the development and commercialization of proprietary product candidates to treat patients suffering from central nervous system (CNS) diseases. The Company is involved in developing roluperidone for the treatment of negative symptoms in patients with schizophrenia and has exclusive rights to develop and commercialize MIN-301 for the treatment of Parkinson’s disease. It has also co-developed seltorexant for the treatment of insomnia disorder and adjunctive treatment of major depressive disorder (MDD). Seltorexant is an innovative selective orexin 2 receptor antagonist. Its Roluperidone is a compound that has been shown to block serotonin, sigma, and α-adrenergic receptors that are involved in the regulation of mood, cognition, sleep and anxiety. Roluperidone has been designed to block a specific subtype of serotonin receptor called 5-HT2A.

Webull offers Minerva Neurosciences Inc stock information, including NASDAQ: NERV real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NERV stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading NERV stock methods without spending real money on the virtual paper trading platform.